Clinical trial · Expanded Access
(Bispecific) Antibodies in Cancer Patients
(Bispecific) Antibodies in Cancer Patients (InHeAb01)
NCT05119257CI-TRIAL-00076924InHeAb01availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this project is to provide (bispecific) antibodies to individual patients with advanced solid and hematological malignancies without any available approved treatment options.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bispecific antibodies (bsAB) | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Documented diagnosis of advanced malignant disease * Advanced malignant disease without any available standard of care treatment option * Live expectancy \> 3 month * Ability to understand and voluntarily sign an informed consent form. * Ability to adhere to the visit schedule and other protocol requirements * Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2. Exclusion Criteria: * Pregnant or lactating females. * Treatment regimens inducing severe T cell deficiencies * Treatment-related side effect from prior cancer treatment \> CTC grade 2 (CTCAE V5.0) * Participation in any clinical study or having taken any investigational therapy, which would interfere with the studys primary and secondary end points within 2 weeks prior to Ab treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.